Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"Radiopharmaceutical Therapy with [¹⁷⁷Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE Cohort.","authors":"Nicolas Garabedian, Timothée Zaragori, Emeline Tabouret, Luc Taillandier, Catherine Ansquer, Edouard Samarut, Sarah Boughdad, Marc Sanson, Caroline Bund, Georges Noël, Catherine Cheze-Le-Rest, Anthony Joncour, Jacques Darcourt, Marie Onno, Gauthier Delaby, Enora Vauleon, Inna Dygai-Cochet, François Ghiringhelli, Emmanuel Deshayes, Julien Boetto, Agathe Edet-Sanson, Adrien Carle-Ortiz, Anthime Flaus, François Ducray, Thibault Fidani, Jean-Sébastien Guillamo, Tatiana Horowitz, Pierre Meneret, Elodie Vauleon, Elske Quak, Jeanne Riverain, Solène Querellou, Vincent Bourbonne, Ghoufrane Tlili, Aymeri Huchet, Lavinia Vija, Justine Attal, Gabriela Hossu, Laetitia Imbert, Betty Salgues, Eric Guedj, Matthieu Peyre, Thomas Graillon, Caroline Boursier, Antoine Verger","doi":"10.2967/jnumed.126.272735","DOIUrl":"https://doi.org/10.2967/jnumed.126.272735","url":null,"abstract":"<p><p>Evidence supporting the efficacy and safety of [¹⁷⁷Lu]Lu-DOTATATE in refractory meningiomas derives mainly from small, single-center studies. The French national multicenter MELUTE study aimed to consolidate these data using a standardized regimen within a compassionate-use program approved by a national multidisciplinary tumor board. <b>Methods:</b> In this retrospective multicenter cohort study, patients with refractory meningiomas treated with [¹⁷⁷Lu]Lu-DOTATATE in 18 French centers between July 2022 and December 2024 were included. Treatment consisted of 7.4 GBq every 8 wk for up to 4 cycles. Clinical data (demographics, histologic World Health Organization grade [WHO], prior treatments, number of cycles, toxicity, progression, survival status as of October 1, 2025) were collected. Baseline [⁶⁸Ga]Ga-DOTATOC PET and brain MRI scans obtained before and after treatment were centrally reviewed. The primary endpoint was 6-mo progression-free survival (PFS) assessed using volumetric Response Assessment in Neuro-Oncology Group criteria. Secondary endpoints were PFS, overall survival (OS), and safety. <b>Results:</b> Sixty-nine patients were included (mean age, 65.1 ± 13.2 y; 52% female): 13 WHO grade 1, 42 WHO grade 2, 8 WHO grade 3, and 6 without histology. Most had prior surgery (86%) or radiotherapy (93%); 32% received prior systemic therapy. Twelve patients (17%) did not complete 4 cycles; only one discontinuation was toxicity-related. Six-month PFS was 70% (95% CI, 58.7-80.4%). Median PFS was 14.6 mo (95% CI, 13.3-18.5 mo), and median OS was 27.6 mo (95% CI, 24.2 mo to not reached). Grade 3 adverse events, mainly lymphopenia, occurred in 16%. Meningioma WHO grade independently predicted PFS, whereas higher Karnofsky performance status and corticosteroid use were protective; worse OS was associated with higher baseline tumor growth rate and prior systemic therapy. <b>Conclusion:</b> MELUTE demonstrates promising efficacy and favorable safety of [¹⁷⁷Lu]Lu-DOTATATE in refractory meningiomas with limited therapeutic options.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal Visual Question Answering System for Survival Prognosis in PSMA-Targeted Radiopharmaceutical Therapy.","authors":"Mohamed Kassar, Jaixi Hu, Isabel Rauscher, Carlos Vinícius Gomes, Thomas Wendler, Sibylle Ziegler, Ali Afshar-Oromieh, Wolfgang A Weber, Axel Rominger, Nassir Navab, Matthias Eiber, Robert Seifert, Kuangyu Shi","doi":"10.2967/jnumed.125.271912","DOIUrl":"https://doi.org/10.2967/jnumed.125.271912","url":null,"abstract":"<p><p>Large language models show great promise for clinical decision support but generally lack medical imaging integration. Therefore, vision-language models have been proposed, but there is little evidence on their performance, particularly compared with conventional machine learning. Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is a well-established treatment for metastatic castration-resistant prostate cancer (mCRPC), but it is still not known which patients will be good long-term responders. Therefore, this study proposes a physician-inspired visual question answering (VQA) framework that emulates the structured integration of PSMA-directed imaging and clinical data used in routine clinical assessment for overall survival prognostication. <b>Methods:</b> As a proof of concept, we conducted a retrospective, multicenter study across 2 academic institutions that included 110 patients with mCRPC who were treated with either [¹⁷⁷Lu]Lu-PSMA I&T or [¹⁷⁷Lu]Lu-PSMA-617. Our VQA approach incorporates a 3-dimensional image encoder, the domain-specific language model RadBERT, and a cross-modal transformer to process baseline and interim (after 2 cycles) PET and SPECT images, clinical data, and clinical query. The model was trained to predict 24-mo survival, and performance was compared with state-of-the-art approaches. External validation was performed with the [¹⁷⁷Lu]Lu-PSMA-617 cohort. <b>Results:</b> The VQA model outperformed all state-of-the-art approaches while showing accuracy comparable to the query-free attention multimodal fusion model. Specifically, it achieved 81.8% accuracy (95% CI, 0.52-0.95) when integrating SPECT or PET images with prostate-specific antigen measurements. External validation of the VQA showed 71.9% accuracy (95% CI, 0.53-0.86) after few-shot fine-tuning, with further improvement over all state-of-the-art approaches in survival stratification. The VQA approach showed the closest calibration with the ground-truth survival distribution, with no significant differences observed (log-rank test, <i>P</i> = 0.76). Receiver operating characteristic analysis showed the highest area under the curve (0.75) among the evaluated models. Together, these findings suggest that the VQA approach demonstrated adaptability across different PSMA ligands while maintaining slightly improved yet comparable overall survival prognostic performance. <b>Conclusion:</b> By adopting a physician-inspired assessment workflow, the VQA framework shows advantages in integrating imaging and laboratory data for clinical decision support compared with conventional machine learning. The preliminary results indicate that VQA-based approaches warrant future evaluation for survival prognostication in patients with mCRPC who are receiving PSMA radiopharmaceutical therapy.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDA Policy Changes on Stability Studies for PET Drugs Manufactured Within Networks.","authors":"Peter J H Scott, Hsiaoju S Lee, Henry F VanBrocklin, D Christian Parr, Michael Nazerias, Ashley Mishoe, Christopher Ignace, Steven S Zigler","doi":"10.2967/jnumed.126.274002","DOIUrl":"https://doi.org/10.2967/jnumed.126.274002","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultra-Low-Dose Long-Axial-Field-of-View [¹⁸F]FDG PET with CT-Free Attenuation Correction for Staging Hodgkin Lymphoma in Pregnancy.","authors":"Hian Liang Huang, Jing Yuan Tan, Yuxin Yang, Young Soon Tay, S Somanesan, Rachel Phoy Cheng Chun, Lay Kok Tan, Francesca Lorraine Lim Wei Inng, Winnie Wing Chuen Lam","doi":"10.2967/jnumed.126.273066","DOIUrl":"https://doi.org/10.2967/jnumed.126.273066","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B7H3-Targeted Molecular Imaging for Highly Specific Diagnosis and In Vivo Noninvasive Detection of B7H3 in Breast Cancer.","authors":"Lei Xia, Ying Gong, Chengxue He, Bo Mei, Yan Zhang, Nina Zhou, Xiangxi Meng, Hua Zhu, Nan Li, Guohong Song, Zhi Yang","doi":"10.2967/jnumed.126.272939","DOIUrl":"https://doi.org/10.2967/jnumed.126.272939","url":null,"abstract":"<p><p>B7 homolog 3 (B7H3) is widely expressed in solid tumors, but its role in the diagnosis of breast cancer is unclear. We aimed to evaluate the diagnostic performance of [⁶⁸Ga]Ga-B7H3-BCH PET/CT in breast cancer patients. <b>Methods:</b> Thirty patients with diverse subtypes of breast cancer underwent both [⁶⁸Ga]Ga-B7H3-BCH and [¹⁸F]FDG PET/CT. Immunohistochemical staining for B7H3 was performed in 25 patients. <b>Results:</b> B7H3 positivity was detected in 84% of samples by immunohistochemistry. [⁶⁸Ga]Ga-B7H3-BCH demonstrated a higher lesion detection rate compared with [¹⁸F]FDG (96.8% vs. 92.4%) among 157 lesions. Median SUV_max was 9.5 in strongly positive lesions; bone metastases had the highest uptake (median SUV_max, 10.9). Imaging resulted in changing the stage or treatment in 8 patients. Hormone receptor-positive/human epidermal growth factor receptor 2-negative lesions showed the highest B7H3 positivity (87.5%) and uptake (median SUV_max, 10.5). <b>Conclusion:</b> [⁶⁸Ga]Ga-B7H3-BCH PET/CT offers high sensitivity for staging advanced breast cancer and noninvasive B7H3 screening. It may influence clinical decisions and appears to reveal subtype-specific uptake, with a tendency to favor hormone receptor-positive/human epidermal growth factor receptor 2-negative disease.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[¹⁸F]F-AraG PET Imaging of Immunometabolic Activity in Individuals Without Malignancy.","authors":"Hee-Don Chae, Tomomi W Nobashi, Uttam Shrestha, Hilda Cabrera, Joseph E Blecha, Henry F VanBrocklin, Robert R Flavell, Youngho Seo, Jelena Levi","doi":"10.2967/jnumed.126.273076","DOIUrl":"https://doi.org/10.2967/jnumed.126.273076","url":null,"abstract":"<p><p>[¹⁸F]F-AraG is a clinical-stage PET tracer in immuno-oncology that accumulates in activated T cells and tissues with high mitochondrial biogenesis. Characterizing its distribution in individuals without malignancy is essential for interpreting immunometabolic states relevant to cancer biology. <b>Methods:</b> Twenty adults without active malignancy underwent a single [¹⁸F]F-AraG PET/CT scan, with tracer uptake assessed in relation to clinical history, medications, and demographic and physiologic factors. <b>Results:</b> Bilateral brown adipose tissue activation was identified in 3 participants receiving potentially brown adipose tissue-activating medications, in the absence of cold exposure or fasting. One showed elevated vertebral bone marrow uptake, previously linked to poor survival in immune checkpoint inhibitor-treated lung cancer. One of 2 participants with breast implants showed asymmetric periimplant uptake. Posterior pulmonary uptake occurred in a subset of participants, often with prior respiratory conditions and thoracic lymph node uptake. <b>Conclusion:</b> Whole-body [¹⁸F]F-AraG PET captures diverse immunometabolic activity in individuals without malignancy, reflecting systemic processes that may influence cancer and treatment outcomes.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and Development of NeuroSphere PET: A Next-Generation 7-T MR-Compatible Dedicated Brain PET Scanner.","authors":"Michele Scipioni, Larry Byars, Magdelena S Allen, James Corbeil, Azma Mareyam, Pablo Galve, Matthew Puryear, Audrey Moos, Fabian Schmidt, Ehsan Kazemivalipour, John Kirsch, Jose M Udias, Lawrence L Wald, Bruce Rosen, Martin Judenhofer, Ciprian Catana","doi":"10.2967/jnumed.125.271971","DOIUrl":"https://doi.org/10.2967/jnumed.125.271971","url":null,"abstract":"<p><p>PET is the most powerful imaging modality for studying neurotransmitters, receptors, and neuromodulation in humans, complementing the anatomic and hemodynamic information provided by MRI. However, PET temporal resolution remains constrained by sensitivity, limiting studies of fast, dynamic neurochemical processes. To address this gap, we are developing the Human Dynamic NeuroChemical Connectome, an imaging system integrating NeuroSphere PET, a novel ultra-high-sensitivity dedicated brain PET camera, with the Siemens Healthineers Magnetom Terra.X, a clinical 7-T MRI scanner. This article describes the design, engineering, and simulation-based performance estimation of NeuroSphere PET. Sensitivity maximization drove 2 core design choices: a partial spheric detector arrangement with a 32-cm inner diameter and 70% solid-angle coverage and the use of 26-mm lutetium oxyorthosilicate crystals for high stopping power (∼90% at 511 keV), coupled to silicon photomultipliers in a light-sharing, depth-of-interaction-capable configuration. The system comprises 872 detector blocks organized across 19 rings and 218 modules. At the detector level, measured performance includes energy resolution of approximately 11% full width at half maximum (FWHM), depth-of-interaction resolution of approximately 8 mm FWHM, and coincidence timing resolution of approximately 500 ps FWHM. System-level performance was evaluated using the ultrafast Monte Carlo PET simulator, accounting for realistic detector response, positron range, photon noncollinearity, and interdetector scatter. Sensitivity was estimated from a 30-cm uniform sphere, predicting a peak sensitivity of about 38% and a whole-brain average exceeding 25%. Spatial resolution and image quality were assessed through Derenzo phantom simulations evaluated at both the center of the field of view and 8 cm off-center, indicating that 1.6-mm structures can be resolved near the center of the field of view and that resolution of less than 2 mm can be maintained at the cortex. The system incorporates a 3-dimensional-printed MRI-compatible gantry, a dedicated 16-channel parallel transmit-receive radiofrequency head coil, and a custom radiofrequency shielding enclosure for simultaneous PET/MRI at 7 T. By targeting sensitivity an order of magnitude higher than that of commercial PET systems, NeuroSphere PET is expected to enable simultaneous neurochemical and hemodynamic studies with substantially improved spatiotemporal resolution, providing new insights into brain function and connectivity.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Streamlining Collaborations to Overcome the Challenges Facing Theranostics Clinical Trials.","authors":"Delphine L Chen, Charlotte Denise Jeffers, Jonathan E McConathy, Dustin Osborne, Kiran K Solingapuram Sai, John J Sunderland, Peter J H Scott","doi":"10.2967/jnumed.126.273904","DOIUrl":"https://doi.org/10.2967/jnumed.126.273904","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical Evaluation on the Radiohybrid Tandem [¹⁸F]La- and [²²⁵Ac]Ac-rhPSMA-10.1 for Targeted α-Therapy of Prostate Cancer.","authors":"Baiqing Sun, Daniel Werner, Juncheng Ni, Silvia Weidle, Katja Steiger, Sepideh Seyfi, Susanne Kossatz, Matthias Eiber, Alfred Morgenstern, Frank Bruchertseifer, Elena-Livia Chilug, Wolfgang A Weber, Calogero D'Alessandria, Alexander Wurzer","doi":"10.2967/jnumed.126.273010","DOIUrl":"10.2967/jnumed.126.273010","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA)-targeted α-therapy holds promise for the treatment of prostate cancer but has increased side effects compared with therapy using β-emitting PSMA ligands. This emphasizes the need for precise imaging of the biodistribution of ²²⁵Ac-labeled ligands for patient selection and dosimetry. However, imaging of [²²⁵Ac]Ac-PSMA ligands remains technically challenging, and no radioactive actinium isotopes with favorable imaging characteristics exist. In this study, we therefore developed radiohybrid ligands that can be labeled with ²²⁵Ac for therapy and ¹⁸F for imaging. <b>Methods:</b> We developed the radiohybrid ligand pair [²²⁵Ac]Ac-rhPSMA-10.1 and [¹⁸F]La-rhPSMA-10.1. Lanthanum was used for the diagnostic agent because no stable actinium isotopes exist, and the ionic chemistry of lanthanum and actinium is similar. The PSMA binding affinity, cellular internalization, and externalization of the ligands were determined. Biodistribution studies of [¹⁸F]La-rhPSMA-10.1 and [²²⁵Ac]Ac-rhPSMA-10.1 versus the reference [²²⁵Ac]Ac-PSMA I&T were performed in LNCaP tumor-bearing mice. For evaluation of the efficacy, LNCaP tumor-bearing mice (<i>n</i> = 6 per group) received a single dose of [²²⁵Ac]Ac-rhPSMA-10.1 or [²²⁵Ac]Ac-PSMA I&T or no treatment. <b>Results:</b> [²²⁵Ac]Ac-rhPSMA-10.1 and [¹⁸F]La-rhPSMA-10.1 showed similar cellular uptake parameters and a similar biodistribution. Compared with [²²⁵Ac]Ac-PSMA I&T, tumor uptake of [²²⁵Ac]Ac-rhPSMA-10.1 was 2.2-fold and 3.5-fold higher at 1 h and 24 h postinjection, respectively, with a similar biodistribution in healthy tissues. In the efficacy study, median survival was 12 d in the control group and more than 50 d for animals treated with [²²⁵Ac]Ac-rhPSMA-10.1 or [²²⁵Ac]Ac-PSMA I&T. Tumor growth was similarly inhibited by [²²⁵Ac]Ac-rhPSMA-10.1 or [²²⁵Ac]Ac-PSMA I&T. <b>Conclusion:</b> [²²⁵Ac]Ac-rhPSMA-10.1/[¹⁸F]La-rhPSMA-10.1 represents a promising theranostic pair that may improve patient selection and dosimetry of α-therapy for prostate cancer.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD70-Targeted PET/CT in a Patient with von Hippel-Lindau Syndrome and Clear Cell Renal Cell Carcinoma.","authors":"Ailin Deng, Weijun Wei","doi":"10.2967/jnumed.126.273553","DOIUrl":"https://doi.org/10.2967/jnumed.126.273553","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}